Virtual Patients...Real Results

Entelos is a life sciences company improving human health through predictive biosimulation. Using in silico disease models and a virtual patient approach, Entelos identifies and validates targets, develops biomarkers, improves the success rates of clinical trials, and helps bring therapeutics to market faster.
News Releases  » Media Coverage  » Events  »
Shareholders Approve Delisting from AIM - June  24
Notice of Annual Meeting of Stockholders and Proxy Statement Relating to Proposed Delisting from AIM and other Matters - June 15
Proposed Delisting from AIM - June 1

Visit Realab™, Entelos' online simulation tool.
FDA to Use Simulation Technology for Drug Testing - Wall Street Journal, December 16, 2008
Today Show interview with author David Ewing Duncan features "The Entelos Prognosis" - Today Show (NBC), March 11, 2009

"How to Save a Trillion Dollars: America needs a Human Genome Project for personalized health care," by David Ewing Duncan - Technology Review, May 6, 2009

For more information on Entelos' work with David Ewing Duncan, please go to www.MyDigitalHealth.com.
Bio IT World - Boston, MA,
April 27 – 29, 2009
For information on Entelos toxicogenomics solutions including DrugMatrix® and ToxFX™, please visit the Iconix website.
Copyright© 2009 Entelos, Inc. All rights reserved Disclaimer (U.S. Visitors)